Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pharming Technologies B.V.

Home Clinical Trial Sponsors and OrganizationsPharming Technologies B.V.

Pharming Technologies B.V.

Vondellaan 47, Leiden, Zuid-Holland, Netherlands

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

55

26 active

Approvals

1

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

19

34.5%

Phase 1

18

32.7%

Phase 3

6

10.9%

Trial Status Distribution

Active, not recruiting

26

47.3%

Completed

18

32.7%

Recruiting

8

14.6%

Terminated

2

3.6%

Withdrawn

1

1.8%

Clinical Trials

Trials sponsored by this organization (55)

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

Jun 202696 participants

Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

Jun 2026140 participants

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

Active, not recruiting

Apr 202512 participants

Leniolisib for Immune Dysregulation in CVID

Feb 202527 participants

Leniolisib for Immune Dysregulation in PIDs

Active, not recruiting

Oct 202412 participants

A trial to test the effect of leniolisib in children from 1 to 6 years of age with APDS

Active, not recruiting

Apr 202415 participants

A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 70 mg film coated tablet in healthy volunteers

Active, not recruiting

Dec 202318 participants

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension

Active, not recruiting

Nov 20232 participants

Page 1 of 7

Approvals

Approvals by Agency

CANADA

Health Canada

1

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials55
Approvals1
News

Back to Organizations